艾塞那肽联合甘精胰岛素对肥胖2型糖尿病效果观察

目的：对艾塞那肽联合甘精胰岛素在2型糖尿病患者中的治疗效果进行观察。方法选取我院2012年4月~2014年4月68例2型肥胖糖尿病患者,将所有患者分成两组,每组34例,1组作为对照组进行胰岛素治疗,2组作为实验组进行艾塞那肽联合甘精胰岛素治疗。治疗后对两组患者的空腹血糖、餐后2h血糖、血脂等情况进行比较。结果实验组平均空腹血糖为(5.83±0.71)mmol/L,餐后2h血糖为(7.32±1.05)mmol/L,糖化血红蛋白水平为(6.15±0.72)%;对照组患者空腹血糖水平为(11.26±1.34)mmol/L,餐后2h血糖为(14.31±2.06)mmol/L,糖化血红蛋白水平(9.93±1.51)%,P<0.05。两组患者胆固醇、甘油三酯、低密度脂蛋白水平存在明显差异,但高密度脂蛋白水平差异不大。结论：艾塞那肽联合甘精胰岛素在2型糖尿病患者中的治疗效果较为显著,能够有效的对患者血糖进行控制,降低患者发病率。     

艾塞那肽对血糖控制不佳的肥胖糖尿病患者疗效分析

目的：观察血糖控制不佳的肥胖2型糖尿病(type 2 diabetes mellitus,T2DM)患者加用艾塞那肽后的疗效。方法：选取研究对象60例(退出3例,实际完成57例),根据不同体重指数(BMI)分为A组(25 kg/m2≤BMI<30 kg/m2)23例,B组(30 kg/m2≤BMI<35 kg/m2)27例,C组(35 kg/m2≤BMI<40 kg/m2)7例,连续给予艾塞那肽治疗12周,比较治疗前后3组患者的临床疗效及血清指标变化。结果：随访结束后,所有患者平均空腹血糖(fasting blood glucose,FBG)水平、HbA1c、体重和BMI、血脂(TC、TG、LDL)等较基线有明显下降(P<0.05);所有患者平均空腹胰岛素(fasting serum insulin,FINS)水平较治疗前有所升高(P>0.05),所有患者HOMA-IR较治疗前明显降低(P均<0.05),HOMA-β较治疗前无显著变化(P>0.05)。3组间比较显示,各组FBG下降幅度C组>B组>A组(P>0.05);HbA1c下降幅度水平C组>A组(P<0.05);体重减轻幅度和BMI的下降幅度依次为C组>B组>A组(P均<0.05)。结论：艾塞那肽可以有效控制血糖控制不佳的肥胖T2DM患者的FBG、HbA1c,改善血脂水平和胰岛功能,减轻体重和BMI。其中,艾塞那肽对FBG、HbA1c、体重、BMI的疗效,在BMI较高组中疗效更显著。     

2型糖尿病男性患者骨代谢指标与骨密度的相关性研究

目的：探讨2型糖尿病男性患者骨密度与骨代谢生化指标间的关系。方法：选取我科2014年1月至2015年12月入院的2型糖尿病男性患者102例,采用双能X线骨密度仪,测定腰椎(L2~L4)、股骨上端[包括股骨颈(Neck)、华氏三角(Ward)及股骨粗隆(Troch)]和全身的骨密度(bone mineral density, BMD)值;根据T值将这些患者分为骨量正常组(44例)、骨量减少组(36例)和骨质疏松组(29例),采用酶联免疫法测定各组碱性磷酸酶(alkaline phosphatase,ALP)、N-端中段骨钙素(N-MID-OT)、总Ⅰ型胶原氨基端延长肽(type 1 amino-terminal propeptide,tP1NP)和β胶原特殊序列(β-CTX)的浓度,比较三组骨代谢指标的变化,并对BMD与各项骨代谢指标进行相关性分析。结果：随着骨密度的降低,骨代谢指标的水平逐渐增高,其中,N-MID-OT和β-CTX的水平在三组间的差异皆有统计学意义(P<0.05);tP1NP在骨质疏松组和其余两组有统计学差异(P<0.05);ALP在三组间无统计学差异(P>0.05)。骨量减少组中,N-MID-OT与Neck、Troch及全身的BMD呈负相关(r=?0.754,?0.663,?0.743;P<0.05),β-CTX与Ward的BMD呈负相关(r=?0.273;P<0.05);骨质疏松组中, N-MID-OT与所有部位的BMD呈负相关(r=?0.736,?0.562,?0.715,?0.521,?0.436;P<0.05),β-CTX与Neck、Ward及全身的BMD呈负相关(r=?0.532,?0.614,?0.764;P<0.05)。结论：2型糖尿病男性患者骨密度与骨代谢指标呈负相关,两者联合评估有助于早期预防骨质疏松。     

2型糖尿病患者骨代谢标志物变化的研究

目的 探讨2型糖尿病(type 2 diabetes mellitus,T2DM)患者骨代谢标志物的变化及其与血糖、血脂代谢的相关性.方法 选取203例T2DM患者作为研究对象,选取同期体检的210例健康人作为对照组,分别测定各组骨代谢指标包括25-羟维生素D[25-hydroxyvitamin D,25(OH)D]、...     

2型糖尿病患者骨代谢生化指标的临床意义

目的 :探讨 2型糖尿病患者骨代谢生化指标的临床意义。方法 :对 4 0例 2型糖尿病患者及 31例正常人进行血骨钙素 (BGP)、钙 (Ca)、碱性磷酸酶 (ALP) ;尿脱氧吡啶啉 (DPD)、Ca、肌酐 (Cr)测定。结果 :糖尿病组血清BGP较正常对照组明显降低 (P <0 0 5 ) ;尿DPD/Cr比值 ,Ca/Cr比值显著高于正常对照组 (P <0 .0 5 ,P <0 .0 5 ) ;血清Ca、ALP两组无统计学差异。结论 :2型糖尿病患者骨代谢异常引发骨量减少、骨质疏松与骨形成减少和骨吸收增加有关 ;血BGP、尿DPD/Cr、Ca/Cr可作为早期诊断糖尿病骨量减少、骨质疏松敏感的骨代谢生化指标。     

男性2型糖尿病患者维生素D营养状况及其对骨代谢指标的影响

目的 了解男性2型糖尿病患者维生素D营养状况及其对骨代谢指标的影响.方法 采用Roche E170全自动电化学发光免疫分析仪检测258例男性2型糖尿病患者血清的25羟维生素D[25(OH)D]、总Ⅰ型前胶原氨基端肽(tPINP)和Ⅰ型胶原羧基端肽(β-CTX).根据血清25 (OH)D水平分为维生素D严重缺乏(＜25nmol/L)、缺乏(≥25nmol/L且＜ 50nmol/L)、不足(≥50nmol/L且＜75 nmol/L)和充足(≥75nmol/L).结果 男性2型糖尿病患者总体25(OH)D浓度为33.80±18.43nmol/L,为维生素D缺乏水平.根据年龄将受试者分为中年组(35 ～49岁)、老年前期组(50 ～ 59岁)、老年1组(60～69岁)、老年2组(＞70岁),发现随着年龄的增长,25(0H)D的浓度呈逐渐降低趋势,老年2组的25(OH)D显著低于中年组(P=0.044),而骨标志物在各年龄组间差异均无统计学意义(P＞0.05).258例男性2型糖尿病患者中维生素D严重缺乏、缺乏、不足、充足的比例分别为36.43％ (94/258)、48.45％(125/258)、11.63％ (30/258)和3.49％ (9/258).维生素D严重缺乏组的β-CTX明显高于其他各营养状况组(均P＜0.05),而tPINP在各营养状况组间差异均无统计学意义(P＞0.05).相关分析表明,血清25(OH)D水平与β-CTX呈负相关(r=-0.197,P=0.001),与tPINP无相关性(r=-0.046,P =0.464).结论 男性2型糖尿病患者存在严重维生素D缺乏和不足状况,维生素D严重缺乏对骨吸收可能有影响.     

辛伐他汀对2型糖尿病患者骨密度的影响

目的 观察辛伐他汀对2型糖尿病患者骨密度的影响。方法 69名2型糖尿病患者，基础对照组(33例，未服用他汀类药物)和辛伐他汀组(36例，服用辛伐他汀)，分别比较两组临床和生化实验室指标，以及骨密度各参数。结果 两组在临床和生化实验室指标上无显著差异。在男性和女性患者中，辛伐他汀组骨密度各参数高于基础对照组，有显著性差异。结论 辛伐他汀可改善微循环障碍和血液流变学异常，可以增加2型糖尿病患者的骨密度。     

女性2型糖尿病患者的骨密度变化

目的：探讨女性2型糖尿病与骨质疏松的关系。方法：应用双能X线骨密度仪（DEXA）对56例女性2型糖尿病患者及52例女性健康对照者进行骨密度（BMD）测定,并测定糖尿病患者的空腹胰岛素及餐后2h胰岛素（2h Ins）水平,结合病程、年龄等相关因素进行分析。结果：52例健康对照组中低骨量8例,骨质疏松5例,骨密度减低的发生率为25%;56例2型糖尿病患者中,低骨量16例,骨质疏松23例,骨密度减低的发生率为69.7%,明显高于对照组,差异有显著性（P〈0.01,χ^2=21.524）,骨密度减低者胰岛素水平相对更低。结论：女性2型糖尿病患者的骨质疏松发生率高,且与年龄、病程、胰岛素水平相关。     

利拉鲁肽联合甘精胰岛素治疗2型糖尿病患者临床疗效

目的:分析2型糖尿病(T2DM)患者采取利拉鲁肽联合甘精胰岛素治疗的临床疗效。方法:选取本院于2016-02-2018-12期间收治的88例T2DM患者,随机分为两组,利拉鲁肽联合甘精胰岛素组作为研究组(n=46),单纯采用甘精胰岛素治疗组作为对照组(n=42),比较两组治疗后空腹血糖(FPG)、餐后2h血糖(2hPG)和糖化血红蛋白(HbAlc)水平变化,甘精胰岛素日用量、血糖达标时间及低血糖发生率。结果:与同组治疗前比较,两组患者治疗后FPG、2hPG、HbAlc水平均降低(P0.01);研究组治疗后FPG、2hPG、HbAlc、甘精胰岛素日使用剂量均低于对照组,血糖达标时间短于对照组,且低血糖发生率低于对照组,差异均有统计学意义(P0.01)。结论:利拉鲁肽联合甘精胰岛素联合治疗T2DM临床疗效显著,能改善血糖水平,减少胰岛素用量,缩短血糖达标时间以及降低不良反应发生率,值得临床推广应用。     

利拉鲁肽联合恩格列净对2型糖尿病患者的效果

目的:探讨利拉鲁肽联合恩格列净对2型糖尿病患者的效果.方法:按照随机数字表法将我院2020年1月至2020年10月期间收治的95例T2DM患者分为两组,对照组47例给予恩格列净治疗,观察组48例在对照组基础上予以利拉鲁肽治疗,观察两组患者临床疗效、胰岛功能、炎症水平以及不良反应发生率.结果:治疗后,观察组总有效率(93...     

Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Bone Mineral Density in Zucker Diabetic Fatty Rats: A Short-Term Comparative Study

BackgroundWhile bariatric surgery could result in weight loss as well as glycaemia improvement, the short-term impact on bone health in a high glycemic environment following Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) remains intriguing.ObjectiveThe aim of this study was to compare the short-term effects of RYGB and SG procedures on bone health in Zucker diabetic fatty (ZDF^fa/fa) rats.MethodsThirty age-matched male ZDF^fa/fa rats were randomized into RYGB, SG, and sham groups after establishment of the diabetic model. Body weight, blood glucose, bone mineral density (BMD), the level of bone turnover markers (BTM), vitamin D, and serum calcium and phosphorus were measured 4 weeks after the operation.ResultsThe RYGB procedure brought about lower blood glucose, BMD, serum calcium and phosphorus levels, as well as a relatively higher bone turnover rate and 1,25(OH)₂VD level, compared to the SG and sham groups, while the influences of the SG procedure were not significant. 25(OH)VD demonstrated no significant difference among the 3 groups.ConclusionsDespite its excellent ability to provide short-term glycemic control, the RYGB procedure could led to more severe impairment of bone health compared to the SG procedure. Bone health should be procured after bariatric surgery, especially with the RYGB procedure. Early detection of BMD and BTM may help to avoid deterioration of bone.     

Microstructural trabecular bone from patients with osteoporotic hip fracture or osteoarthritis: Its relationship with bone mineral density and bone remodelling markers

Osteoporosis (OP) and osteoarthritis (OA) are the most prevalent musculoskeletal disorders in the elderly but the relationship between them is unclear. The purposes of this study are to analyze the bone turnover markers (BTM), bone mineral density (BMD) and the structural and mechanical properties of trabecular bone in patients with OP and OA, and to explore the relationship between these two diseases. We studied 12 OP patients and 13 OA patients. We analyzed BTM (β-CrossLaps and PINP), BMD and microstructural and biomechanical parameters (micro-CT). Our results were: OP group has higher levels of β-CrossLaps and lower BMD at the femoral neck. Also, OP patients have a decreased volume of trabecular bone and less trabecular number, with architecture showing prevalence of rod-like trabeculae and worse connectivity than OA patients. The biomechanical parameters were worse in OP patients. BMD was correlated with almost all the structural and biomechanical parameters. Moreover, β-CrossLaps was negatively correlated with hip BMD and with bone surface density and positively with trabecular separation. BTM, BMD and bone microstructural changes in osteoporosis are opposite to those of OA. These findings justify a less resistant bone with higher risk of fragility fractures in OP patients. These histomorphometric and biomechanical changes may be suspected by measuring of BMD and β-CrossLaps levels.     

Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women

Objective: To analyse the interest of baseline levels and short-term (3-months) changes in serum osteocalcin (BGP), serum bone-specific alkaline phosphatase (BALP) and urinary C-telopeptide of type I collagen/creatinine ratio (U-CTX) to predict 3-years changes in bone mineral density (BMD) and spinal deformity index (SDI) in postmenopausal osteoporotic women. Methods: Data were derived from a cohort of 603 osteoporotic women corresponding to the placebo arm of a 3-years prospective, double-blind study. Results: Baseline values of BALP, BGP and U-CTX were negatively and significantly correlated with baseline spinal BMD. Significant correlations were also observed between the changes in BMD observed after 36 months at the spine and baseline BALP (r=0.20, P=0.0001), BGP (r=0.09, P=0.05) and U-CTX (r=−0.11, P=0.02). At 3 years, 71 women (15.9%) showed an increase in their SDI, corresponding to the occurrence of at least one new vertebral deformity. Baseline values of the four bone turnover markers (BTM) were not significantly related to the occurrence of new vertebral deformities. However, when considering the changes in the BTM observed after 3-months of follow-up, BGP (P=0.003) and U-CTX (P=0.047) were identified as significant predictors of an increase of SDI. The associated odds ratios (95% confidence interval (CI)) were 10.922 (2.218–53.78) for unit changes of log BGP and 1.369 (1.003–1.867) for unit changes of log U-CTX. The relative risk (RR) (IC 95%) of having a new vertebral fracture over 36 months was 0.31 (0.15–0.65) when being in the lowest quartile of 3-months changes in BGP as compared with the highest. Conclusion: We conclude that two sequential measurements of BGP and U-CTX performed at 3-months intervals could be of interest to identify postmenopausal osteoporotic women with the highest risk to present new vertebral deformities.     

糖尿病相关骨转换指标研究进展

骨质疏松症是糖尿病常见并发症之一,也是影响糖尿病患者生存质量及寿命的主要原因.骨密度(bone mineral density,BMD)测定是早期诊断骨质疏松的标准,然而,一些BMD正常的潜在骨质疏松患者易被忽略.因此,寻找敏感性和特异性更高的骨代谢标志物来预测早期骨代谢异常具有重要意义.     

胰岛素强化治疗在2型糖尿病骨折患者围手术期的应用

Objective To investigate the best way to control the blood sugar level during the perioperation of bone fracture patients with type 2 diabetes(T2DM).Methods Bone fracture patients with T2DM were randomly divided into three groups:continuous subcutaneous insulin infusion group(insulin aspart,group CSII,n=20),glargine treatment group(insulin aspart+insulin glargine,group GA,n=20),and NPH treatment(insulin aspart+rh-insulin,group NA,n=20).The levels of fasting plasma glucose(FPG)and the 2 hours postprandial glucose(2h PG),blood glucose fluctuation(BGF),insulin dosage(ID),good effective time(GET),incidence of hypoglycemia,dawn phenomenon and infection,average time of stitches removal(ATSR),average hospitalized length(AHL)of three groups were compared.Results FPG and 2hPG,ID in group CSII[(6.32±1.18)mmol/L,(7.72±1.53)mmol/L,(35.40±1.60)IU]and group GA [(6.25±0.88)mmol/L,(7.32±1.17)mmol/L,(36.20±0.80)IU]were significantly lower than those of group NA [(7.44±1.36)mmol/L,(8.52±0.76)mmol/L,(40.50±2.40)IU,all P<0.05],simulaneously,BGF,GET incidence of complications,ATSR,AHL of group CSII and GA were significantly lower than those of group NA(all P<0.05).There were not significant difference between group CSII and group GA.Compared with group CSII,group GA had less costs in-hospital and better practicability.Conclusion Both CSII and insulin glargine combined with insulin aspart can effectively,safely,rapidly and stablely control hyperglycemia.and might be the first choice to control blood sugar for bone fracture patients with T2DM in perioperation.     

胰岛素强化治疗在2型糖尿病骨折患者围手术期的应用

Objective To investigate the best way to control the blood sugar level during the perioperation of bone fracture patients with type 2 diabetes(T2DM).Methods Bone fracture patients with T2DM were randomly divided into three groups:continuous subcutaneous insulin infusion group(insulin aspart,group CSII,n=20),glargine treatment group(insulin aspart+insulin glargine,group GA,n=20),and NPH treatment(insulin aspart+rh-insulin,group NA,n=20).The levels of fasting plasma glucose(FPG)and the 2 hours postprandial glucose(2h PG),blood glucose fluctuation(BGF),insulin dosage(ID),good effective time(GET),incidence of hypoglycemia,dawn phenomenon and infection,average time of stitches removal(ATSR),average hospitalized length(AHL)of three groups were compared.Results FPG and 2hPG,ID in group CSII[(6.32±1.18)mmol/L,(7.72±1.53)mmol/L,(35.40±1.60)IU]and group GA [(6.25±0.88)mmol/L,(7.32±1.17)mmol/L,(36.20±0.80)IU]were significantly lower than those of group NA [(7.44±1.36)mmol/L,(8.52±0.76)mmol/L,(40.50±2.40)IU,all P<0.05],simulaneously,BGF,GET incidence of complications,ATSR,AHL of group CSII and GA were significantly lower than those of group NA(all P<0.05).There were not significant difference between group CSII and group GA.Compared with group CSII,group GA had less costs in-hospital and better practicability.Conclusion Both CSII and insulin glargine combined with insulin aspart can effectively,safely,rapidly and stablely control hyperglycemia.and might be the first choice to control blood sugar for bone fracture patients with T2DM in perioperation.     

胰岛素强化治疗在2型糖尿病骨折患者围手术期的应用

Objective To investigate the best way to control the blood sugar level during the perioperation of bone fracture patients with type 2 diabetes(T2DM).Methods Bone fracture patients with T2DM were randomly divided into three groups:continuous subcutaneous insulin infusion group(insulin aspart,group CSII,n=20),glargine treatment group(insulin aspart+insulin glargine,group GA,n=20),and NPH treatment(insulin aspart+rh-insulin,group NA,n=20).The levels of fasting plasma glucose(FPG)and the 2 hours postprandial glucose(2h PG),blood glucose fluctuation(BGF),insulin dosage(ID),good effective time(GET),incidence of hypoglycemia,dawn phenomenon and infection,average time of stitches removal(ATSR),average hospitalized length(AHL)of three groups were compared.Results FPG and 2hPG,ID in group CSII[(6.32±1.18)mmol/L,(7.72±1.53)mmol/L,(35.40±1.60)IU]and group GA [(6.25±0.88)mmol/L,(7.32±1.17)mmol/L,(36.20±0.80)IU]were significantly lower than those of group NA [(7.44±1.36)mmol/L,(8.52±0.76)mmol/L,(40.50±2.40)IU,all P<0.05],simulaneously,BGF,GET incidence of complications,ATSR,AHL of group CSII and GA were significantly lower than those of group NA(all P<0.05).There were not significant difference between group CSII and group GA.Compared with group CSII,group GA had less costs in-hospital and better practicability.Conclusion Both CSII and insulin glargine combined with insulin aspart can effectively,safely,rapidly and stablely control hyperglycemia.and might be the first choice to control blood sugar for bone fracture patients with T2DM in perioperation.     

胰岛素强化治疗在2型糖尿病骨折患者围手术期的应用

Objective To investigate the best way to control the blood sugar level during the perioperation of bone fracture patients with type 2 diabetes(T2DM).Methods Bone fracture patients with T2DM were randomly divided into three groups:continuous subcutaneous insulin infusion group(insulin aspart,group CSII,n=20),glargine treatment group(insulin aspart+insulin glargine,group GA,n=20),and NPH treatment(insulin aspart+rh-insulin,group NA,n=20).The levels of fasting plasma glucose(FPG)and the 2 hours postprandial glucose(2h PG),blood glucose fluctuation(BGF),insulin dosage(ID),good effective time(GET),incidence of hypoglycemia,dawn phenomenon and infection,average time of stitches removal(ATSR),average hospitalized length(AHL)of three groups were compared.Results FPG and 2hPG,ID in group CSII[(6.32±1.18)mmol/L,(7.72±1.53)mmol/L,(35.40±1.60)IU]and group GA [(6.25±0.88)mmol/L,(7.32±1.17)mmol/L,(36.20±0.80)IU]were significantly lower than those of group NA [(7.44±1.36)mmol/L,(8.52±0.76)mmol/L,(40.50±2.40)IU,all P<0.05],simulaneously,BGF,GET incidence of complications,ATSR,AHL of group CSII and GA were significantly lower than those of group NA(all P<0.05).There were not significant difference between group CSII and group GA.Compared with group CSII,group GA had less costs in-hospital and better practicability.Conclusion Both CSII and insulin glargine combined with insulin aspart can effectively,safely,rapidly and stablely control hyperglycemia.and might be the first choice to control blood sugar for bone fracture patients with T2DM in perioperation.